NASDAQ:MYLMylan Stock Price, Forecast & News

Mylan's stock was trading at $14.47 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MYL shares have increased by 10.1% and is now trading at $15.93. View which stocks have been most impacted by Coronavirus.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mylan in the last year. There are currently 6 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Mylan.

Mylan is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Mylan.

Mylan NV (NASDAQ:MYL) posted its quarterly earnings data on Monday, May, 11th. The company reported $0.90 EPS for the quarter, topping analysts' consensus estimates of $0.86 by $0.04. The firm had revenue of $2.62 billion for the quarter, compared to the consensus estimate of $2.65 billion. Mylan had a net margin of 0.54% and a return on equity of 20.00%. The company's revenue was up 5.0% on a year-over-year basis. During the same quarter last year, the business posted $0.82 earnings per share. View Mylan's earnings history.

Mylan updated its FY 2020 Pre-Market earnings guidance on Monday, May, 11th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $11.5-12.5 billion, compared to the consensus revenue estimate of $11.74 billion.

12 equities research analysts have issued twelve-month target prices for Mylan's stock. Their forecasts range from $17.00 to $34.50. On average, they anticipate Mylan's stock price to reach $23.75 in the next twelve months. This suggests a possible upside of 49.1% from the stock's current price. View analysts' price targets for Mylan.

Media stories about MYL stock have been trending negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Mylan earned a news impact score of -2.1 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news about Mylan.

Mylan saw a increase in short interest during the month of June. As of June 15th, there was short interest totaling 31,480,000 shares, an increase of 13.8% from the May 31st total of 27,660,000 shares. Based on an average daily trading volume, of 7,360,000 shares, the short-interest ratio is currently 4.3 days. Approximately 6.1% of the company's shares are short sold. View Mylan's Current Options Chain.

Some companies that are related to Mylan include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics (HZNP), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX), Corcept Therapeutics (CORT) and Zogenix (ZGNX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Mylan investors own include Gilead Sciences (gild), Alibaba Group (BABA), Teva Pharmaceutical Industries (TEVA), Pfizer (PFE), NVIDIA (NVDA), Micron Technology (MU), Starbucks (SBUX), Intel (INTC), Cisco Systems (CSCO) and CVS Health (CVS).

Mylan trades on the NASDAQ under the ticker symbol "MYL."

Mylan's stock is owned by many different retail and institutional investors. Top institutional investors include State of Alaska Department of Revenue (0.08%) and Corrado Advisors LLC (0.01%). Company insiders that own Mylan stock include Goulds Bruce, Melina E Higgins, Paul Campbell, Richard A Mark, Robert J Coury and Sjoerd S Vollebregt. View institutional ownership trends for Mylan.

MYL stock was sold by a variety of institutional investors in the last quarter, including Corrado Advisors LLC. View insider buying and selling activity for Mylan.

MYL stock was purchased by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have bought Mylan stock in the last two years include Melina E Higgins, Richard A Mark, Robert J Coury, and Sjoerd S Vollebregt. View insider buying and selling activity for Mylan.

Shares of MYL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MYL stock can currently be purchased for approximately $15.93.

Mylan has a market capitalization of $8.24 billion and generates $11.50 billion in revenue each year. The company earns $16.80 million in net income (profit) each year or $4.42 on an earnings per share basis. Mylan employs 35,000 workers across the globe.

The official website for Mylan is www.mylan.com.

Mylan's mailing address is 1000 MYLAN BOULEVARD, CANONSBURG PA, 15317. The company can be reached via phone at 724-514-1800 or via email at [email protected]